4.4 Review

Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy

期刊

DRUG DEVELOPMENT RESEARCH
卷 76, 期 8, 页码 419-427

出版社

WILEY
DOI: 10.1002/ddr.21285

关键词

immune-mediated inflammatory diseases; psoriasis; rheumatoid arthritis; inflammatory bowel disease; safety; infection; malignancy; anti-TNFa therapies

资金

  1. AbbVie
  2. MSD
  3. Ferring
  4. OM Pharma
  5. Amgen
  6. Novartis
  7. Boeringher
  8. Menarini
  9. Glaxo-Smith-Klein
  10. Boehringer Ingelheim
  11. Janssen
  12. Leo-Pharma
  13. Pfizer

向作者/读者索取更多资源

The efficacy of anti-TNF agents in the treatment of multiple immune-mediated inflammatory diseases (IMIDs) has increased their daily use. However, concerns remain regarding their long-term safety profile. Using a literature-based review of the infectious and malignant complications of anti-TNF biologics in IMIDs including psoriasis, Rheumatoid Arthritis, and inflammatory bowel disease, this review presents current evidence relative to the safety of anti-TNF agents in the context infections and malignancy in adults with IMIDs. Treatment with anti-TNF biologics is an effective treatment option with known risks that can be mitigated by appreciating the safety aspects and via a thorough screening and continuous monitoring of the patient. (C) 2015 Wiley Periodicals, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据